Update under Regulation 30 read with Para A Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
MEDPLUS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Optival Health Solutions Private Limited, a subsidiary of Medplus, has received a suspension order for the Drug License of one of its stores located in Karnataka. The order was issued by the Assistant Director, Drugs Control Administration, Bangalore Circle – Davanagere, and was received on July 21, 2025. The suspension is for two days under Rule 65 of the Drugs and Cosmetics Act, 1940. The potential revenue loss is approximately Rs 0.64 lacs (around Rs 64,000), which is a very minor financial impact. This is a routine regulatory action affecting only a single store and does not materially affect the company's overall operations.
Negligible impact on the company — the revenue loss of about Rs 0.64 lacs from a 2-day suspension of a single store is immaterial for a company of Medplus's size. No meaningful effect expected on stock price or shareholder value.